BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

ArcherDX picks deal with Invitae over IPO  Genetic testing company Invitae (NYSE:NVTA) is acquiring ArcherDX Inc., adding a cancer diagnostics platform to its precision oncology business. ArcherDX’s shareholders will receive $325 million in cash plus...
BioCentury | Jun 2, 2020

June 1 Quick Takes: CHMP recommendations, plus FDA action on AbbVie-Neurocrine, Shionogi, AZ, Lilly, Genentech

CHMP backs Ebola vaccine, targeted cancer therapies  EMA’s CHMP recommended approval of a two-component Ebola vaccine -- Zabdeno and Mvabea -- from Johnson & Johnson (NYSE:JNJ) Friday. The agency also backed two targeted cancer therapies:...
BioCentury | May 15, 2020
Product Development

May 14 ASCO Quick Takes: Alphamab rises on responses for pair of bispecific mAbs; plus ImmunoGen and CytomX

Alphamab bispecifics against checkpoints, pair of HER2 sites  In an abstract released ahead of this month’s American Society of Clinical Oncology virtual meeting, Alphamab Oncology Ltd. (HKEX:9966) reported data from a Phase I trial showing...
BioCentury | May 12, 2020
Product Development

May 11 Quick Takes: Genfit’s elafibranor misses in NASH Phase III; plus AstraZeneca, Merck, Protalix and TolerogenixX

Genfit’s PPAR agonist fails to resolve NASH  Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) fell $10.88 (49%) to $11.22 in after-hours trading Monday after reporting that dual PPARα/δ agonist elafibranor missed the primary endpoint of the Phase III...
BioCentury | Apr 24, 2020
Product Development

April 23 Quick Takes: Hansoh, NiKang partner for antiviral; plus Jakafi, Avastin, EpimAb-QIMR, ProThera-Takeda

Hansoh gains China rights to NiKang antiviral  Hansoh Pharmaceutical Group Co. Ltd. (HKEX:03692) gained rights to develop and commercialize NKT-1992 from NiKang Therapeutics Inc. for viral diseases in Greater China. NiKang is eligible to receive...
BioCentury | Mar 5, 2020

Amunix’s Omega-led $73M A round to support shift to drug development

The potential for Amunix’s protein polymer technology to overcome toxicity issues that have plagued two growing immuno-oncology modalities convinced Omega Funds to lead the biotech’s $73 million series A. The round, together with cash from...
BioCentury | Feb 14, 2020

On heels of reimbursement, Innovent raises $303M to ready Tyvyt rollout

Within one month of its stock reaching an all-time high, Innovent priced its second follow-on offering on the Hong Kong exchange early Thursday, raising HK$2.4 billion ($303.2 million) to expand manufacturing capacity in preparation for...
BC Extra | Jan 25, 2020
Company News

Pfizer seeking to dent market share with trio of discounted biosimilars

Pfizer is hoping that discounts of 22-24% from reference drugs’ wholesale acquisition costs (WACs) will help it gain market share for three new or soon-to-be launched biosimilars, each of which will compete with at least...
BC Extra | Jan 17, 2020
Company News

Jan. 17 Company Quick Takes: FDA expands label of Novo’s Ozempic; plus Intercept, Durect, Coherus-Innovent, CoImmune-Formula and Momenta

Label expansion for Novo’s Ozempic  FDA approved Ozempic subcutaneous semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NOVO) to reduce the risk of major adverse cardiovascular events in adults with Type II diabetes and heart disease....
BC Extra | Jan 13, 2020
Company News

Jan. 13 Company Quick Takes: AZ ends fish oil trial; plus Lynparza, Lilly-NextCure, Innovent, Amgen-Qiagen-Guardant, Axsome-Pfizer

AstraZeneca ends CV outcomes trial of Epanova  AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued the Phase III STRENGTH trial after an IDMC determined it is unlikely to show that Epanova improved cardiovascular outcomes in patients with mixed...
Items per page:
1 - 10 of 1685